Tonix Pharmaceuticals Holding (TNXP) Interest Expenses (2011 - 2026)
Tonix Pharmaceuticals Holding (TNXP) posted quarterly Interest Expenses of $144000.0 for Q1 2026, up 23.08% year-over-year from $117000.0 in Q1 2025, and up 311.43% quarter-over-quarter from $35000.0 in Q3 2025.
Tonix Pharmaceuticals Holding (TNXP) Interest Expenses (2011 - 2026) Analysis & Trends
Tonix Pharmaceuticals Holding's Interest Expenses history runs 16 years deep, the most recent figure standing at $144000.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 23.08% year-over-year to $144000.0; the TTM figure through Mar 2026 stood at $144000.0 (up 785.71% YoY), while the FY2025 annual figure was $6.1 million, down 90.28% from the prior year.
- Interest Expenses for Q1 2026 stood at $144000.0, up from $35000.0 in the prior quarter.
- The five-year high for Interest Expenses was $1.8 million in Q1 2024, with the low at -$346000.0 in Q4 2023.
- The 5-year median for Interest Expenses is $147500.0 (2022), against an average of $487000.0.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses surged 4100.0% in 2022, then plunged 329.14% in 2023.
- Tonix Pharmaceuticals Holding's Interest Expenses stood at $151000.0 in 2022, then plunged by 329.14% to -$346000.0 in 2023, then surged by 120.23% to $70000.0 in 2024, then slumped by 50.0% to $35000.0 in 2025, then jumped by 311.43% to $144000.0 in 2026.
- Business Quant data shows TNXP's Interest Expenses at $144000.0 in Q1 2026, $35000.0 in Q3 2025, and $42000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Tonix Pharmaceuticals Holding | 213.43 Mn | 213.43 Mn | 12.84 Mn | 1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.40 Mn |
| Jun 30, 2026 | 1.40 Mn |
| Mar 31, 2026 | 144,000.00 |
| Mar 31, 2026 | 144,000.00 |
| Sep 30, 2025 | 35,000.00 |
| Sep 30, 2025 | 35,000.00 |
| Jun 30, 2025 | 42,000.00 |
| Jun 30, 2025 | 42,000.00 |
| Mar 31, 2025 | 117,000.00 |
| Mar 31, 2025 | 117,000.00 |
| Dec 31, 2024 | 70,000.00 |
| Dec 31, 2024 | 70,000.00 |
| Sep 30, 2024 | 1.36 Mn |
| Sep 30, 2024 | 1.36 Mn |
| Jun 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 1.57 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Dec 31, 2023 | -346,000.00 |
| Dec 31, 2023 | -346,000.00 |